BioCentury | Jun 2, 2020
Regulation

June 1 Quick Takes: CHMP recommendations, plus FDA action on AbbVie-Neurocrine, Shionogi, AZ, Lilly, Genentech

CHMP backs Ebola vaccine, targeted cancer therapies  EMA’s CHMP recommended approval of a two-component Ebola vaccine -- Zabdeno and Mvabea -- from Johnson & Johnson (NYSE:JNJ) Friday. The agency also backed two targeted cancer therapies:...
BioCentury | May 28, 2020
Product Development

Daily Chart: TIGIT pipeline heats up

With last week’s data from Genentech, the next-generation checkpoint target TIGIT has started to out-shine its peers. At least 11 TIGIT inhibitors are coming up behind Genentech’s tiragolumab in the pipeline. The Roche unit released...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 21, 2020
Product Development

May 20 Quick Takes: Filgotinib meets in ulcerative colitis; broader labels for Lynparza, Tecentriq, plus updates from Eiger, eGenesis and more

High dose filgotinib meets ulcerative colitis endpoints  A 200 mg dose of filgotinib from Gilead Sciences Inc. (NASDAQ:GILD) and Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) met the primary endpoints in the placebo-controlled Phase IIb/III SELECTION trial to...
BioCentury | May 18, 2020
Finance

$65M round positions SQZ Biotech for potential IPO, 2021 catalysts

SQZ Biotech is adding at least one experienced crossover investor to what could be its last private financing ahead of catalysts expected late this year and next. SQZ Biotechnologies Co. raised $65 million in a...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
BioCentury | Apr 29, 2020
Product Development

Highlights from AACR’s first annual virtual meeting show mixed results for I/O combos, promise for new targets, modalities

Immuno-oncology combinations showed mixed results at the first of two virtual annual meetings this year of the American Association for Cancer Research, with PD-L1 inhibitor Tecentriq atezolizumab reporting two negative readouts and uninspiring monotherapy data...
BioCentury | Apr 25, 2020
Product Development

AACR Primer: first virtual AACR meeting of year will include data from over 40 trials

Data from an allogeneic CAR T therapy, bispecific mAbs and new immuno-oncology combinations are some of the highlights expected at the first virtual meeting of the year for the American Association for Cancer Research. Due...
BioCentury | Apr 6, 2020
Product Development

Immunomedics doubles in value on Phase III update for TNBC therapy ahead of June PDUFA; names Semerjian CEO

After halting a Phase III trial early due to efficacy in the difficult setting of triple-negative breast cancer, Immunomedics named a new, commercially-experienced CEO to help the biotech transition into a commercial launch phase. Immunomedics...
BioCentury | Mar 5, 2020
Finance

Amunix’s Omega-led $73M A round to support shift to drug development

The potential for Amunix’s protein polymer technology to overcome toxicity issues that have plagued two growing immuno-oncology modalities convinced Omega Funds to lead the biotech’s $73 million series A. The round, together with cash from...
Items per page:
1 - 10 of 340